Myeloproliferative neoplasms
60 views | +0 today
Follow
Your new post is loading...
Your new post is loading...
Scooped by Ken Young
Scoop.it!

Myeloproliferative Neoplasm (MPN) Symptom Assessment Form ...

Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs. Robyn M.
Ken Young's insight:

Score card for MPN

more...
No comment yet.
Scooped by Ken Young
Scoop.it!

The role of 18F-FDG PET/CT for the diagnosis of inf... [Leuk Res. 2013] - PubMed - NCBI

PubMed comprises more than 22 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
Ken Young's insight:

A interesting study from Harvard

more...
No comment yet.
Scooped by Ken Young
Scoop.it!

Prevalence

Prevalence | Myeloproliferative neoplasms | Scoop.it
Prevalence of the myeloproliferative neoplasms in the united states
Ken Young's insight:

Interesting prevelence data

more...
No comment yet.
Scooped by Ken Young
Scoop.it!

Concept Grants Awarded for Myelofibrosis Research

Concept Grants Awarded for Myelofibrosis Research | Myeloproliferative neoplasms | Scoop.it
Chicago, IL and White Plains, NY (PRWEB) July 10, 2013 -- The MPN Research Foundation and The Leukemia & Lymphoma Society announce winners of year two of the Myelofibrosis Challenge.
Ken Young's insight:

Great news. The research initiatives on MPN is gathering pace

more...
No comment yet.
Scooped by Ken Young
Scoop.it!

Clinical implications of diagnostic discrepancies in myelofibrosis

Clinical implications of diagnostic discrepancies in myelofibrosis | Myeloproliferative neoplasms | Scoop.it
The impact of  myelofibrosis misdiagnosis on patient outcomes  can be serious. In this M.D. Anderson study, presented at ASCO in Chicago last month, those implications were analyzed.  The original ...
more...
No comment yet.
Scooped by Ken Young
Scoop.it!

Polycythemia Vera -- the lack of consensus

Polycythemia Vera -- the lack of consensus | Myeloproliferative neoplasms | Scoop.it
Damned if you do, damned if you don’t  Despite advances in our understanding of the pathogenesis of MPNs, processes for risk stratification and therefore indications for cytoreduction lack better r...
more...
No comment yet.
Scooped by Ken Young
Scoop.it!

Nathalie's discovery

Nathalie's discovery | Myeloproliferative neoplasms | Scoop.it
by Nathalie Cook Over the past 10 or so years, I developed increasingly frequent headaches and occasional spots in my peripheral vision. As a busy mother I dismissed them as migraines, took paracet...
Ken Young's insight:

From Nathalie a dietician based in Melbourne

more...
No comment yet.
Scooped by Ken Young
Scoop.it!

Food for Thought ... Nathalie Cook

Food for Thought ... Nathalie Cook | Myeloproliferative neoplasms | Scoop.it
Show me the color of your food My husband, an engineer, pronounced as he looked at his dinner plate,  “There are five main food groups…” Wow, he’s been listening. And he goes on to say, “...green, ...
Ken Young's insight:

From Nathalie a dietician based in Melbourne

more...
No comment yet.
Rescooped by Ken Young from Amazing Science
Scoop.it!

Several Janus kinase (JAK) Pathway Inhibitors in Clinical Trials

Several Janus kinase (JAK) Pathway Inhibitors in Clinical Trials | Myeloproliferative neoplasms | Scoop.it

Janus kinase (JAK) plays an important role in the formation and development of blood cells, and defects in the gene have been identified in myeloproliferative neoplasms. As a result, JAK inhibitors for the treatment of hematologic malignancies have been an intense research focus, with one drug receiving approval in 2011 and several more in various stages of clinical development. In November, the FDA approved ruxolitinib (Jakafi; Incyte) for the treatment of intermediate or high-risk myelofibrosis, in which dysregulation of the JAK1 and JAK2 pathways results in a depletion of healthy bone marrow that burdens the liver and spleen. In the phase III COMFORT-I study, 41.9% of patients receiving ruxolitinib had at least a 35% reduction in spleen size, and 45.9% of patients on the drug reported a reduction in symptoms.

 

Other JAK inhibitors are being assessed in clinical trials. These include:

• Ruxolitinib: Incyte is continuing to develop the drug for several hematologic malignancies. A phase III trial is ongoing in polycythemia vera, a phase II study is under way in essential thrombocythemia vera, and phase I/II evaluations are continuing in advanced leukemias and other hematologic malignancies.

• CYT387 (YM BioSciences): Two ongoing phase II trials are evaluating dosing, safety, and tolerability of the oral JAK1 and JAK2 inhibitor as monotherapy for patients with myelofibrosis. Results presented at the American Society of Hematology (ASH) Meeting in 2011 indicated significant durable response in anemia, splenomegaly, and constitutional symptoms, particularly at the 300- mg once-daily dose level.

• SAR302503 (TG101348, Sanofi): A highly selective oral JAK2 inhibitor, SAR302503 is being tested in a phase III clinical trial that is currently enrolling patients with myelofibrosis. In an interim phase I/II analysis presented at ASH 2011, spleen responses were usually seen within the first three cycles, with 54.4% of patients achieving ≥ 50% spleen reduction after six months and 66.7% of patients achieving the same endpoint after 12 months.

• LY2784544 (Eli Lilly): In the results of a phase I trial that were presented at ASH 2011, spleen reduction of at least 35% was observed in 13 of 17 evaluable patients (76%) with myeloproliferative neoplasm subtypes. A questionnaire found that 59% of patients reported symptom improvement ≥ 50%.


Via Dr. Stefan Gruenwald
Ken Young's insight:

This is great to see new drugs being developed for MPNs. I hope that trials happen in Australia to give early access for Australian patients

more...
No comment yet.
Scooped by Ken Young
Scoop.it!

Life with essential thrombocytosis

I was diagnosed with Essential Thrombocytosis in Jan 2011 by an Oncologist cum Haemo. My age at the time of diagnoses of ET was 43.  I was lucky that I found it out before I lost my left thumb.  It...
Ken Young's insight:

Interesting personal story

more...
No comment yet.
Scooped by Ken Young
Scoop.it!

"Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H1 2013 ... - SBWire (press release)

"Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H1 2013 ... - SBWire (press release) | Myeloproliferative neoplasms | Scoop.it
"Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H1 2013 ...
more...
No comment yet.
Scooped by Ken Young
Scoop.it!

Cancer's Mighty Mite | HMS

Cancer's Mighty Mite | HMS | Myeloproliferative neoplasms | Scoop.it
http://t.co/xkGCgQVdpL "inhibition of miR-22 through a “decoy”.. offers a novel therapeutic option for treating hematological malignancies"
more...
No comment yet.
Scooped by Ken Young
Scoop.it!

Genomic imprinting maintains a reserve pool of blood-forming stem cells in mouse bone marrow

Hematopoietic stem cells -- bone marrow-derived adult stem cells that give rise to the wide variety of specialized blood cells -- come in two flavors: the reserve force sits quietly waiting to be called upon while the active arm continually...
more...
No comment yet.
Scooped by Ken Young
Scoop.it!

Mechanisms underlying blood disorders identified

Mechanisms underlying blood disorders identified | Myeloproliferative neoplasms | Scoop.it
Scientists have uncovered a protein structure that regulates cell signalling and the formation of blood cells.
Ken Young's insight:

Great research that has implications for MPN disorders

more...
No comment yet.
Scooped by Ken Young
Scoop.it!

The MPNclinic Roundtable: How I diagnose MPNs.

The MPNclinic Roundtable:   How I diagnose MPNs. | Myeloproliferative neoplasms | Scoop.it
MPN is a rare disease, debilitating and potentially deadly. There is no cure beyond risky SCT, but with proper management a normal life is possible for most patients. The key to therapy is accurate...
more...
No comment yet.
Scooped by Ken Young
Scoop.it!

Michiels on Dameshek -- the evolving view of polycythemia vera

Michiels on Dameshek -- the evolving view of polycythemia vera | Myeloproliferative neoplasms | Scoop.it
The image of William Dameshek hovers over myeloproliferative neoplasm – and hematology itself – like that of a founding father.  In fact, much of contemporary diagnostics, research, and treatment o...
more...
No comment yet.
Scooped by Ken Young
Scoop.it!

"Should I be Scared?"

"Should I be Scared?" | Myeloproliferative neoplasms | Scoop.it
(I promise the title of this entry will make sense eventually...) So this past Wednesday I had the privilege of attending the Chicagoland MPN Patient Support Meeting. (Thank goodness for understand...
Ken Young's insight:

A great story

more...
No comment yet.
Scooped by Ken Young
Scoop.it!

Food for Thought -- November

Food for Thought --  November | Myeloproliferative neoplasms | Scoop.it
Tummy Troubles by Nathalie Cook I often find myself discussing 'tummy troubles' with people who come to see me in my professional role as an Accredited Practising Dietitian (APD), at my Melbourne b...
Ken Young's insight:

From Nathalie a dietician based in Melbourne

more...
No comment yet.
Rescooped by Ken Young from Model Organisms in Genetics Research
Scoop.it!

Novel Genetic Findings for Myeloproliferative Neoplasms | The ...

Novel Genetic Findings for Myeloproliferative Neoplasms | The ... | Myeloproliferative neoplasms | Scoop.it

23andMe scientist David Hinds will present findings from a study on myeloproliferative neoplasms, or MPNs, at an upcoming genetics conference.


Via Rubén García García
Ken Young's insight:

This reserach is very valuable study and the independant researh work that 23andMe undertake. I extend my personal thanks to Anne Wojcicki and Sergey Brin for making this work possible.

more...
No comment yet.
Scooped by Ken Young
Scoop.it!

Revised response criteria for polycythemia vera and essential thrombocythemia: a ELN and IWG-MRT consensus project

Revised response criteria for polycythemia vera and essential thrombocythemia: a ELN and IWG-MRT consensus project | Myeloproliferative neoplasms | Scoop.it
Ken Young's insight:

New criteria could be more helpful for patients

more...
No comment yet.
Scooped by Ken Young
Scoop.it!

Acute embolic cerebral ischemia as an initial presentation of polycythemia ... - 7thSpace Interactive (press release)

Acute embolic cerebral ischemia as an initial presentation of polycythemia ...
Ken Young's insight:

A useful insight

more...
No comment yet.